The correlation of IL28B genotypes with patient demographics and disease characteristics in patients with Genotype 1 chronic hepatitis C
Not Applicable
Completed
- Conditions
- hepatitis Cgenotype 1antiviral treatment naiveInfection - Other infectious diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disorders
- Registration Number
- ACTRN12611000846921
- Lead Sponsor
- Australian Liver Association Clinical Trial Network
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
hepatitis C (HCV)
genotype 1
evidence of hepatitis C infection for at least 6 months
Serological evidence of HCV infection by an anti-HCV antibody test (current or historical)
Exclusion Criteria
1. Infection with any HCV genotype other than genotype 1. Patients with indeterminate or mixed subtypes will be allowed.
2. Patients currently treated, or a history of having received any interferon or ribavirin based therapy or investigational anti-HCV agents at any previous time.
3. Patients co-infected with hepatitis B, or HIV
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ational distribution of the IL28B genotypes for both the rs12979860 and rs8099917 SNPs.<br><br>Both SNPs will be tested through blood testing.[At the end of recruitment]
- Secondary Outcome Measures
Name Time Method To see if there is any correlation between the IL28B genotype and pre-treatment factors such as the extent of liver fibrosis, viral load and HCV genotype 1, Self reported ethnicity years of infection and fibrosis staging ,treatment initiation status post testing and 6 and 12 months post genotyping.<br>All the above parameters will be collected from patients and their medical records and entered into a database.[12 months after recruitment]